Avanos Medical (AVNS) Stock Price, News & Analysis

Company Overview

Avanos Medical, Inc. is a global medical technology company specializing in the design, development and manufacture of healthcare solutions for pain management, enteral feeding and respiratory care. Its product portfolio includes infusion systems and surgical fluid warming devices for enhanced patient comfort, regional anesthesia pumps and catheter‐based therapies for post‐operative pain control, as well as feeding tube and pump technologies that support enteral nutrition for critically ill patients. Through its respiratory care offerings, Avanos provides airway clearance and breathing assistance products for individuals with chronic respiratory conditions.

Founded in 2014 as a spin‐off from Kimberly‐Clark’s healthcare business, Avanos has built upon decades of medical device experience to establish a broad global footprint. The company’s flagship brands encompass on‐demand analgesia systems, such as the ON-Q® and PainBuster® families, along with Volara® warming platforms and a range of feeding and respiratory solutions marketed under proprietary names. These products are distributed to hospitals, surgical centers and home healthcare providers in more than 70 countries.

Headquartered in Alpharetta, Georgia, Avanos operates manufacturing facilities across North America, Europe and Asia, supported by research and development centers that focus on human factors engineering and clinical innovation. Its leadership team draws on deep expertise in medical device commercialization, quality assurance and regulatory affairs, while the board of directors includes veterans of global healthcare and industrial technology sectors. Together, they guide Avanos’s strategy of expanding its core franchises and exploring adjacent therapy areas.

Looking ahead, Avanos Medical continues to invest in next‐generation delivery systems, minimally invasive pain management technologies and enhanced nutritional products. By leveraging clinical partnerships and a growing international sales organization, the company aims to drive sustainable growth and deliver value to both patients and healthcare customers worldwide.

Key Stats

• Today's Range: $11.35 to $11.71
• 50-Day Range: $11.46 to $13.12
• 52-Week Range: $11.21 to $25.36
• Volume: 509,850 shs
• Average Volume: 389,748 shs
• Market Capitalization: $540.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Avanos Medical Stock Analysis - MarketRank™

Avanos Medical scored higher than 58% of companies evaluated by MarketBeat, and ranked 488th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Avanos Medical.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 31.06%

Earnings Growth

Earnings for Avanos Medical are expected to grow by 31.06% in the coming year, from $1.32 to $1.73 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avanos Medical is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avanos Medical is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avanos Medical has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.26% of the float of Avanos Medical has been sold short.

Short Interest Ratio / Days to Cover

Avanos Medical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avanos Medical has recently decreased by 12.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avanos Medical does not currently pay a dividend.

Dividend Growth

Avanos Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.26% of the float of Avanos Medical has been sold short.

Short Interest Ratio / Days to Cover

Avanos Medical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avanos Medical has recently decreased by 12.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.41

News Sentiment

Avanos Medical has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Avanos Medical this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avanos Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.64% of the stock of Avanos Medical is held by insiders.

Percentage Held by Institutions

95.17% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVNS Stock Analysis - Frequently Asked Questions

How have AVNS shares performed this year?

Avanos Medical's stock was trading at $15.92 at the beginning of 2025. Since then, AVNS stock has decreased by 26.8% and is now trading at $11.6530.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) issued its quarterly earnings data on Tuesday, May, 6th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. The business's revenue for the quarter was up .8% compared to the same quarter last year.
Read the conference call transcript.

Who are Avanos Medical's major shareholders?

Avanos Medical's top institutional investors include State of Alaska Department of Revenue (0.06%), Counterpoint Mutual Funds LLC (0.05%), Wealth Enhancement Advisory Services LLC (0.05%) and Janney Montgomery Scott LLC (0.03%). Insiders that own company stock include Michael Greiner, Kerr Holbrook and Julie Ann Shimer.
View institutional ownership trends.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avanos Medical investors own include JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Home Depot (HD), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:AVNS
• CIK: 1606498
• Web: avanos.com
• Phone: (844) 428-2667
• Fax: N/A
• Employees: 2,227
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($8.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.83
• P/E Growth: N/A
• Net Income: -$392.10 million
• Net Margins: -55.80%
• Pretax Margin: -57.33%
• Return on Equity: 6.26%
• Return on Assets: 4.63%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 2.57
• Quick Ratio: 1.56

Sales & Book Value

• Annual Sales: $687.80 million
• Price / Sales: 0.78
• Cash Flow: $12.01 per share
• Price / Cash Flow: 0.97
• Book Value: $18.03 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 46,240,000
• Free Float: 45,023,000
• Market Cap: $538.83 million
• Optionable: Optionable
• Beta: 1.12